Serum Proteomic Profile Based on the TGF‐β Pathway Stratifies Risk of Hepatocellular Carcinoma
Liver International · 2025
DOI: 10.1111/liv.70325 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, 2025. Verfasst von Xiyan Xiang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine, The Institute for Bioelectronic Medicine, Feinstein Institutes for Medical Resea…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Liver Cirrhosis, Transforming Growth Factor beta. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIAAA NIH HHS, NIH HHS.
Abstract (Originalsprache)
Background
Hepatocellular carcinoma (HCC) is the third leading cause of cancer‐related deaths, primarily due to late‐stage diagnosis. In this multicenter study, our goal is to identify functional biomarkers that stratify the risk of HCC in patients with cirrhosis (CP) for early diagnosis.
Methods
Five thousand and eight serum proteins (Somascan) were analysed in Cohort A (477 CP, including 125 HCC). Clustering analysis of the TGF‐β pathway‐associated protein signature was performed in a longitudinal, prospective Cohort B (312 CP, in which 18 cases developed HCC over a 5‐year follow‐up period). Next, a multivariable prediction model was built using logistic regression analysis of cross‐sectional data from a matched subgroup ( n = 328, Cohort C). Model performance was 10‐fold cross‐validated across the entire Cohort A ( n = 477).
Results
Longitudinal follow‐up analysis revealed that patients with elevated TGF‐β‐related protein signature displayed a five‐fold increased risk of developing HCC (9.68% vs. 1.91%). Compared to cirrhosis, serum MSTN, TGFBR2, and AFP levels raised in HCC were validated by ELISA ( n = 200, odds ratio = 1.4–2.9, p < 0.05). In Cohort C, 88 proteins were significantly altered in HCC compared to cirrhosis ( p < 0.05). The six‐protein panel (TGFBR2, MSTN, AFP, COL18A1, GLUL, TP63) displayed a strong performance in the matched cohort C (AUC 0.87, sensitivity 0.88, specificity 0.72), alongside four clinical factors (Age, Sex, BMI, Bilirubin). A 10‐fold cross‐validation demonstrated a mean AUC of 0.86 in cohort A, with strong predictive power in obese/MASLD/ALD‐related patients (AUCs: 0.862–0.921).
Conclusions
The mechanism‐based panel effectively stratifies HCC risk in cirrhotic patients, underscoring the need for Phase II/III validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Medicine, The Institute for Bioelectronic Medicine, Feinstein Institutes for Medical Research & Cold Spring Harbor Laboratory, Northwell Health, Manhasset, New…
- Division of Gastroenterology and Hepatology, Department of Medicine, The University of Maryland, School of Medicine, Baltimore, Maryland, USA.
- Department of Epidemiology, The University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
- Department of Surgery, University of Hawaii, Honolulu, Hawaii, USA.
- Department of Pathology and Laboratory Medicine, Ronald Reagan Medical Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
- Division of Hepatology, Northwell Health, and Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
ORCID-Profile: James M Crawford
Förderung
- NCI NIH HHS
- NIAAA NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Xiang, X., Shetty, K., Yu, H., Mishra, B., Wong, L. L., Zhou, X. J., Satapathy, S. K., Crawford, J. M., Latham, P. S., Han, S. H., Mathew, B., Dagher, N. N., Lau, L., Cacaj, F., Vegesna, A. K., Dasarathy, S., He, A. R., Huang, H., Amdur, R. L., & Mishra, L. (2025). Serum Proteomic Profile Based on the TGF‐β Pathway Stratifies Risk of Hepatocellular Carcinoma. Liver International. https://doi.org/10.1111/liv.70325
Vancouver
Xiang X, Shetty K, Yu H, Mishra B, Wong LL, Zhou XJ, et al. Serum Proteomic Profile Based on the TGF‐β Pathway Stratifies Risk of Hepatocellular Carcinoma. Liver International. 2025. doi:10.1111/liv.70325
BibTeX
@article{Xiang2025,
author = {Xiang, Xiyan and Shetty, Kirti and Yu, Herbert and Mishra, Bibhuti and Wong, Linda L and Zhou, Xianghong Jasmine and Satapathy, Sanjaya K and Crawford, James M and Latham, Patricia S and Han, Steven-Huy and Mathew, Brandon and Dagher, Nabil N and Lau, Lawrence and Cacaj, Fellanza and Vegesna, Anil K and Dasarathy, Srinivasan and He, Aiwu R and Huang, Hai and Amdur, Richard L and Mishra, Lopa},
title = {Serum Proteomic Profile Based on the TGF‐β Pathway Stratifies Risk of Hepatocellular Carcinoma},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.70325}
}
EUVIMED